In vitro and in vivo characterization of a novel liposomal a butorphanol formulation for treatment of pruritus

Grace J. Lim, Yozo Ishiuji, Aerlyn Dawn, Benjamin Harrison, Do Won Kim, Anthony Atala, Gil Yosipovitch

Research output: Contribution to journalArticle

18 Scopus citations


As yet no transdermal topical formulations have been developed for the treatment of chronic itch. We developed a formulation containing 2 mg butorphanol tartrate in 100 μl purified water encapsulated into multilamel-lar phospholipid vesicles. Drug permeation experiments were studied with Franz diffusion chambers using human skin in vitro and on rat skin in vivo. Histological analysis of rat skins was performed to evaluate skin irritation of the formulation in vivo. Physical properties showed stable formulation with desirable viscosity. In vitro dermal penetration rate data suggest that there was significant permeation at time-points 2 h and 4 h, and a steady state was achieved afterwards to 24 h. Maximal plasma butorphanol concentration was noted at 2 h and steady state was achieved at 8 h. Visual skin assessment as well as histological analysis of excised rat skin did not demonstrate any evidence of inflammation and irritation. In vitro and in vivo analysis demonstrated release of a consistent amount of butorphanol in a sustained manner for 24 h. This liposomal transdermal delivery formulation could serve as a method to deliver butorphanol for patients with chronic pruritus.

Original languageEnglish (US)
Pages (from-to)327-330
Number of pages4
JournalActa dermato-venereologica
Issue number4
StatePublished - Jul 28 2008



  • Butorphanol
  • Kappa-opioid
  • Liposome
  • Pruritus
  • Transdermal delivery

ASJC Scopus subject areas

  • Dermatology

Cite this